First Patient Dosed in Phase 1 Trial of IMS001 Therapy

First Patient Dosed in Phase 1 Trial of IMS001 Therapy

312663

First Patient Dosed in Phase 1 Trial of IMS001 Therapy

ImStem Biotechnology announced that the first patient in its Phase 1 clinical trial for IMS001, an investigational treatment for multiple sclerosis (MS), has been dosed at the Shepherd Center in Atlanta. The trial (NCT04956744) is recruiting participants with an MS diagnosis ages 18 to 65. More information is available on this link. “On behalf of our research team, we are excited to have been the first site in the US to dose an MS patient…

You must be logged in to read/download the full post.